

To: Keystone First and Keystone First Community HealthChoices (CHC) Providers

Date: October 30, 2023

RE: Hepatitis C Agents on the Preferred Drug List (PDL) no longer require prior authorization within quantity limits

We would like to remind you that effective July 10, 2023, Preferred direct-acting antivirals in the “Hepatitis C Agents” class on the Pennsylvania Statewide Preferred Drug List (PA PDL) no longer require prior authorization when prescribed within quantity limits. This update is pursuant to Medical Assistance Bulletin (MAB) 2023062905, issued by PA Department of Human Services (DHS) on June 29, 2023.

Please note that prior authorization is still required for Non-Preferred agents in this class and for any request (Preferred or Non-Preferred) that exceeds quantity limits.

In addition, all Hepatitis C Agents remain designated as Specialty drugs for Keystone First and Keystone First CHC and, therefore, must still be dispensed via a pharmacy included in Keystone First and Keystone First CHC’s Specialty Pharmacy network.

Feel free to access the PA Preferred Drug List on the DHS website at PA PDL: <https://papdl.com>.

To utilize the Plan formulary, go to www.keystonefirstpa.com → Pharmacy → Formulary or www.keystonefirstchc.com → Providers → Pharmacy Services.

If you have any questions regarding this change, please contact Keystone First Pharmacy Services at 1-800-588-6767 or Keystone First CHC Pharmacy Services at 1-866-907-7088.